ClinicalTrials.gg
CompletedNCT00332007Updated Aug 31, 2009

Tonabersat in the Prophylaxis of Migraine With Aura

A Phase 2 interventional study of Tonabersat and Placebo in Migraine With Aura, sponsored by Minster Research Ltd. Completed at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-08-31.

Sponsored by Minster Research Ltd · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Migraine with Aura with a site in Denmark — 2 open to participants now, 2 under way, none of them phase 3. Migraine with Aura · Denmark.

Enrollment
8th of 18
39 · median 33
Started
2006
with 2 others
Phase 2
3 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
2 of 20
Minster Research Ltd

Among the 20 studies in Migraine with Aura with a site in Denmark, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2006, is one of 3 in phase 2, and was the 2nd registered.

Migraine with Aura

114 studies on the registry are indexed under Migraine with Aura; 21 are open to participants now.

Browse Migraine with Aura studies →

Open to participants now

2 of the 20 studies in Migraine with Aura with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 17 Migraine with Aura studies recruiting now, 7 (41%) set no upper age limit and 9 (53%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Migraine with Aura with a site in Denmark, or all of them as a file.
02

Study summary

Overall trial objectives:

  1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura
  2. How well tolerated is treatment with tonabersat

The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment

03

Conditions studied

  • Migraine With Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an established history of migraine of at least one year meeting the diagnostic criteria of the International Classification of Headache Disorders - Edition 2 (Appendix 2) and who experience at least one aura a month.
  • Male or female patients between 18-65 years of age
  • Women of child bearing potential must be using a reliable form of (defined in the protocol) for at least 3 months prior to enrolment and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period

Exclusion criteria

Exclusion Criteria:

  • Patients experiencing headache other than migraine or tension headache
  • Overuse of acute migraine treatments defined as more than 14 daily doses per month with analgesics or more than 9 daily doses per month of ergots or triptans within the last two months
  • Migraine prophylactic treatment within two months prior to entry to the trial
  • Patients taking any of the following medications for migraine: beta-blockers, tricyclic antidepressants (during the last 2 months), antiepileptic dugs (during the last 2 months), calcium channel blockers, monoamine oxidase inhibitors, daily NSAIDs, daily paracetamol, high dose magnesium supplements (600mg/day). Parenteral administration of botulinum toxin is also excluded. These drugs are permitted when given for diseases other than migraine provided that, in the opinion of the investigator the dose can be kept constant throughout the trial.
  • Patients who, in the opinion of the investigator, have significant cerebrovascular disease e.g. , stroke
  • Patients who, in the opinion of the investigator, have cardiovascular disease
  • Patients suffering from a current clinical diagnosis of a major depressive disorder or schizophrenia
  • Patients with renal dysfunction , defined as a serum creatinine of greater than 125% of the for their age group
  • Patients with hepatic dysfunction defined as a liver function test (, ALT, alkaline phosphatase, ) of greater than twice the upper limit of normal for their age group
  • Patients with known alcohol or other substance abuse
  • Use of an drug (for any indication) within 30 days or 5 half-lives, whichever is the longer, prior to screening
  • Women who are pregnant or breast feeding
  • Women of not using a reliable form of
  • Patients with any other clinically significant condition which, in the investigators opinion, would render them unsuitable for this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    1

    Tonabersat 40 mg daily

    Drug: Tonabersat

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • two tablets once daily

  • DrugPlacebo

    two tablets once daily

06

What researchers measure

Primary outcomes

  1. Difference in the mean number of aura attacks experienced between treatment groups

    Time frame: 12 week treatment period

  2. Difference in the mean number of migraine headache days between treatment groups

    Time frame: 12 week treatment period

  3. Incidence of adverse events

    Time frame: 12 week treatment period

Secondary outcomes

  1. Mean number of headache days in each treatment period.

    Time frame: 12 week treatment period

  2. Mean number of auras followed by headache in each treatment period.

    Time frame: 12 week treatment period

  3. Mean number of headache days in each month of treatment in each treatment period.

    Time frame: Mean monthly

  4. Mean number of auras and/or migraine headache during each treatment period.

    Time frame: 12 week treatment period

  5. Mean number of migraine headache attacks in each treatment period.

    Time frame: 12 week treatment period

  6. Speed of effect of treatment.

    Time frame: First month for which difference between treatments identified

  7. Mean monthly consumption of rescue medication.

    Time frame: Mean monthly

  8. Mean duration of auras in each treatment period.

    Time frame: Mean over 12 week treatment period

  9. Mean number of symptoms associated with auras in each treatment period.

    Time frame: 12 week treatment period

07

Study locations

1 site
  • Danish Headache Centre, Department of Neurology, Glostrup Hospital
    Copenhagen, Denmark
08

References and documents

Publications

  • International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine (second edition). Cephalalgia 2000; 20:765-86. Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products for the treatment of migraine, CPMP/EWP/788/01/Final. London, 17 December 2003.
  • Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products for the treatment of migraine, CPMP/EWP/788/01/Final. London, 17 December 2003.
  • Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009 Aug;8(8):718-23. doi: 10.1016/S1474-4422(09)70135-8. Epub 2009 Jun 29. PubMed 19570717 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2006
First posted
May 31, 2006
Start
May 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Aug 31, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332007
Lead sponsor
Minster Research Ltd
First posted
May 31, 2006
Start date
May 2006
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Aug 31, 2009

Study contacts

Jes Olesen, MD
principal investigator · University of Copenhagen, Department of Neurology, Glostrup Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonabersat

Start the discussion